KCNN4 promoted gemcitabine resistance in breast cancer models by activating RAS-MAPK and PI3K-AKT signaling and subsequently upregulating of BCL2A1 protein levels, and its expression predicted poor disease-free survival (Lin et al., 2020). Here, AKT1 is linked to breast carcinoma.